Esq JD - AIM ImmunoTech CEO Chairman
| AIM Stock | USD 0.23 0.02 9.52% |
Insider
Esq JD is CEO Chairman of AIM ImmunoTech
| Age | 69 |
| Address | 2117 SW Highway 484, Ocala, FL, United States, 34473 |
| Phone | 352 448 7797 |
| Web | https://aimimmuno.com |
AIM ImmunoTech Management Efficiency
The company has Return on Asset of (0.8004) % which means that on every $100 spent on assets, it lost $0.8004. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.5479) %, meaning that it generated no profit with money invested by stockholders. AIM ImmunoTech's management efficiency ratios could be used to measure how well AIM ImmunoTech manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to grow to -1.61. In addition to that, Return On Capital Employed is likely to grow to -2.83. At this time, AIM ImmunoTech's Total Assets are very stable compared to the past year. As of the 29th of November 2024, Non Current Assets Total is likely to grow to about 8.5 M, while Intangible Assets are likely to drop about 1.3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kenneth MD | Cue Biopharma | 64 | |
| Quinn Deveraux | Inhibrx | N/A | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Dr III | Cue Biopharma | 48 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| BS CPA | Inhibrx | 42 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Mark Lappe | Inhibrx | 57 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| James JD | Eliem Therapeutics | 58 | |
| , MBA | Molecular Partners AG | 51 | |
| Steven Almo | Cue Biopharma | 63 | |
| JD MSc | Cue Biopharma | 61 | |
Management Performance
| Return On Equity | -1.55 | ||||
| Return On Asset | -0.8 |
AIM ImmunoTech Leadership Team
Elected by the shareholders, the AIM ImmunoTech's board of directors comprises two types of representatives: AIM ImmunoTech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AIM. The board's role is to monitor AIM ImmunoTech's management team and ensure that shareholders' interests are well served. AIM ImmunoTech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AIM ImmunoTech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wayne Springate, Senior Vice President - Operations | ||
| III Esq, Exec COO | ||
| Ann Coverly, Director Coordinator | ||
| MBA IV, Chief Officer | ||
| Jodie Pelz, Director Finance | ||
| Stewart Appelrouth, Director | ||
| Ellen Lintal, Chief Financial Officer | ||
| Christopher McAleer, Scientific Officer | ||
| Esq JD, CEO Chairman | ||
| David Strayer, Chief Scientific & Medical Officer | ||
| William Mitchell, Chairman of the Board | ||
| Peter Rodino, Executive Director - Governmental Relations, General Counsel | ||
| Thomas Equels, Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel | ||
| David MD, Chief Director | ||
| Ralph Cavalli, Vice Manufacturing | ||
| Carol Smith, Chief Officer |
AIM Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AIM ImmunoTech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.55 | ||||
| Return On Asset | -0.8 | ||||
| Operating Margin | (73.88) % | ||||
| Current Valuation | 10.72 M | ||||
| Shares Outstanding | 63.71 M | ||||
| Shares Owned By Insiders | 8.57 % | ||||
| Shares Owned By Institutions | 14.07 % | ||||
| Number Of Shares Shorted | 491.37 K | ||||
| Price To Earning | 12.50 X | ||||
| Price To Book | 4.99 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.47) | Revenue Per Share 0.004 | Quarterly Revenue Growth 0.19 | Return On Assets (0.80) | Return On Equity (1.55) |
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.